1 DEVELOPMENT OF TOLERANCE AND DEPENDENCE IN BARBITURATE USE: A SYSTEMS MODELING APPROACH by Ali Osman Konuray B.S., Chemical Engineering, Istanbul Technical University, 25 Submitted to the Institute for Graduate Studies in Science and Engineering in partial fulfillment of the requirements for the degree of Master of Science Graduate Program in Industrial Engineering Boaziçi University 28
2 ii DEVELOPMENT OF TOLERANCE AND DEPENDENCE IN BARBITURATE USE: A SYSTEMS MODELING APPROACH APPROVED BY: Prof. Yaman Barlas (Thesis Supervisor) Assist. Prof. Aybek Korugan... Assoc. Prof. Cengizhan Öztürk... DATE OF APPROVAL:
3 iii ACKNOWLEDGEMENTS I am deeply grateful to Professor Yaman Barlas, my thesis supervisor, for being a great example of an enthusiastic scientist. Without him, I would never indulge the field of System Dynamics which seemed, at first, very distinct from my scientific background. His contribution to my studies in recent years is invaluable. I would like to thank Assist. Prof. Aybek Korugan and Assoc. Prof. Cengizhan Öztürk for taking part in my thesis jury and providing valuable feedback. I would like to thank Ceyhun Eksin and Genco Fas for their company, during and after intense academic moments. I would also like to thank members of SESDYN Research Group for their support and friendship, and all the bright people in the department for contributing to my academic development. years. I would like to thank Süheyla Ayar for sharing her life with me in the last couple of I would like to express my deepest gratitude to my mother Gülsün Konuray for inspiring me with her artistic personality. Her wisdom is my guiding light. Lastly, I would like to thank my late father Dr. M. Mehmet Konuray for installing in me an unfailing respect for science.
4 iv ABSTRACT DEVELOPMENT OF TOLERANCE AND DEPENDENCE IN BARBITURATE USE: A SYSTEMS MODELING APPROACH A system dynamics model is constructed to study the development of tolerance and dependence to phenobarbital in prolonged use. Phenobarbital is a sedative barbiturate drug whose target of action is the brain. Although its use has decreased over the years, phenobarbital is still being prescribed to many patients. As a side effect, phenobarbital enhances the synthesis of its own metabolic enzymes in the liver. This enzyme induction problem causes increased tolerance to phenobarbital over time. Moreover, the brain adapts to the presence of the drug and its sensitivity decreases with time. The resulting decrease in drug effectiveness urges the drug user to increase the dose. A feedback loop results, as the increased dose in turn leads to more metabolic induction and neuroadaptation. Furthermore, the brain s adaptation to the drug plays a major role in rendering the user dependent on the drug hence complicating withdrawal from the drug. Because adaptive changes persist even after drug intake stops, upon abrupt discontinuation to the drug, the user experiences unwanted rebound effects. The model incorporates phenobarbital absorption, distribution, metabolism, and elimination processes with enzyme induction and neuroadaptation related structures. We start with validating the model by assuming a normal person. We then consider three scenarios: An epilepsy patient, a normal person taking an enzyme inhibitor drug concurrently with phenobarbital, and a normal person adopting different dosing schemes. We finally search for dosing regimens that facilitate gradual withdrawal from the drug so that rebound effects are avoided. Results show that an epilepsy patient is more prone to developing tolerance and dependence. Also, it is shown that concurrent intake of an enzyme inhibitor drug weakens rebound effects after sudden discontinuation since phenobarbital is cleared slower. Experiments with dosing frequencies show that the patient is more prone to tolerance and dependence development if dosing frequency is decreased. Finally, experiments confirm that in order to withdraw from the drug safely, doses should be reduced gradually.
5 v ÖZET BARBTURAT KULLANIMINDA TOLERANS VE BAIMLILIK OLUUMU: BR SSTEM MODELLEMES Sürekli fenobarbital kullanımında tolerans ve baımlılık oluumunu aratırmak için bir sistem dinamii modeli kurulmutur. Fenobarbital, beyni etkileyen sedatif (sakinletirici) bir ilaçtır. Geçmi yıllara kıyasla kullanımı azalmı olmasına ramen bir çok insan halen fenobarbital kullanmaktadır. Fenobarbital bir yan etki olarak kendini metabolize eden karacier enzimlerinin sayısını arttırır. Bu enzim artıı ilaca tolerans oluumuna neden olur. Bunun yanında, zamanla beyin ilaca adapte olur ve dolayısıyla ilaca karı hassasiyeti azalır. Bu iki faktör, ilacın etkinliini azalttıından kullanıcının aynı etkiyi hissedebilmesi için dozu arttırması gerekir. Artan dozlar metabolizma ve nöroadaptasyon etkilerini güçlendirerek kısır bir geri bildirim döngüsü oluturur. Nöroadaptasyon, kullanıcıyı ilaca baımlı kılarak ilacın bırakılmasını zorlatırır. laç alımı kesilmesine ramen adaptif deiimler hemen yokolmaz ve dolayısıyla kullanıcı ilacı bıraktıktan kısa bir süre sonra yoksunluk sendromu yaar. Kurulan model, fenobarbital ilacının emilimi, daılımı, metabolizması ve atılımı süreçlerini içermektedir. Enzim artıı ve nöroadaptasyon mekanizmaları da modele eklenmitir. Tezde öncelikle normal bir insan ele alınmakta ve model empirik veriler kullanılarak gerçeklenmektedir. Bunun ardından, bir epilepsi hastasının, bir enzim inhibitörüyle birlikte fenobarbital kullanan bir insanın, ve normal bir insanın uyguladıı farklı doz uygulamalarının modellendii üç ayrı senaryo incelenmitir. Son olarak yoksunluk sendromunu engelleyebilecek doz stratejileri ile deneyler yapılmıtır. Sonuçlar epilepsi hastalarının tolerans ve baımlılık geliimine daha hassas olduklarını göstermitir. Dier taraftan, fenobarbital ile beraber enzim inhibitörü bir ilaç alınırsa, fenobarbital vücuttan daha yava atılmakta, dolayısıyla da fenobarbital alımı aniden kesildiinde ortaya çıkan yoksunluk sendromunun iddeti daha az olmaktadır. Farklı doz stratejileriyle yapılan deneylerde, doz alım sıklıı azaldıkça tolerans ve baımlılık geliiminin hızlandıı görülmütür. Son olarak, yoksunluk sendromundan kaçınmak için, dozun kademeli bir ekilde azaltılması gerektii gösterilmitir.
6 vi TABLE OF CONTENTS ACKNOWLEDGEMENTS... iii ABSTRACT... iv ÖZET... v LIST OF FIGURES... viii LIST OF TABLES... xi LIST OF ABBREVIATIONS... xii 1. INTRODUCTION Neurotransmission in the Central Nervous System Definition of Pharmacokinetics Pharmacokinetics of Barbiturates Action mechanism of barbiturates Development of Tolerance and Dependence to Barbiturates RESEARCH OBJECTIVE AND DYNAMIC HYPOTHESIS METHODOLOGY MODEL DESCRIPTION Pharmacokinetics Sector Fundamental Approach and Assumptions Description of the Structure Central Nervous System Sector Fundamental Approach and Assumptions Description of the Structure Dose Sector Fundamental Approach and Assumptions Description of the Structure Model Parameters VALIDATION OF THE MODEL Simulation Results Single Dose Continuous Drug Intake with Constant Dose... 4
7 vii Continuous Drug Intake with Dose Increase as a Result of Feedback Drug Treatment for Seven Days Drug Treatment for 2 Days Drug Treatment for 6 Days Model Validity Discussion SCENARIO ANALYSES Epilepsy Patient Co-administration of a Drug That Causes Enzyme Inhibition Different Dosing Frequencies ANALYSIS OF WITHDRAWAL POLICIES Withdrawal after 2 days of treatment An unsuccessful regimen A successful regimen Withdrawal after 6 days of treatment An unsuccessful regimen A Successful Regimen CONCLUSIONS AND FUTURE RESEARCH DIRECTIONS APPENDIX. EQUATIONS OF THE MODEL... 8 REFERENCES... 89
8 viii LIST OF FIGURES Figure 1.1. Relative safety of barbiturates and benzodiazepines... 1 Figure 1.2. Frequency of barbiturate use among twelfth grade high school students... 2 Figure 1.3. Different types of synapses (top). A schematic representation of neurotransmission (bottom)... 5 Figure 1.4. Steps in excitatory and inhibitory neurotransmission... 6 Figure 1.5. Blood plasma concentration time data for a single IV dose of thiopental... 8 Figure 1.6. GABA A receptor-chloride channel complex... 9 Figure 1.7. Pre- and post-synaptic neuroinhibition by barbiturates... 1 Figure 1.8. Proposed mechanism of enzyme induction by phenobarbital Figure 1.9. Administered doses of PB Figure 1.1. Change in the intensity of rebound behavior with time Figure The Himmelsbach hypothesis Figure 2.1. Causal loop diagram for tolerance and dependence development Figure 4.1. Stock-flow structure of the pharmacokinetics sector Figure 4.2. Saturability of enzyme induction Figure 4.3. Concentration-response data for phenobarbital Figure 4.4. Stock-flow structure of the CNS sector Figure 4.5. Graphical function for IndAdptnRate Figure 4.6. Graphical function for EffSatur... 3 Figure 4.7. Graphical function for EffAdptnOnNormClCur Figure 4.8. Graphical function for EffPBOnReadptn Figure 4.9. Stock-flow structure for the Dose Sector Figure 5.1. Absorption and distribution of a single dose Figure 5.2. Increasing chloride current in the brain after a single dose Figure 5.3. Dynamics of enzyme induction and neuroadaptation for a single dose... 4 Figure 5.4. Constant doses (a) and drug profiles in the brain (b) in both a seven day and a 2 day treatment Figure 5.5. Enzyme induction and neuroadaptation and the resulting chloride current profile when the user takes constant doses (for seven and 2 days)... 42
9 ix Figure 5.6. Dose profile (a) and drug amount in the brain (b) in the seven day drug treatment followed by abrupt withdrawal Figure 5.7. Enzyme and neuroadaptation dynamics in the seven day drug treatment followed by abrupt withdrawal Figure 5.8. Behavior of chloride current in the seven day drug treatment Figure 5.9. Dose profile (a) and drug amount in the brain (b) in the 2 day drug treatment followed by abrupt withdrawal Figure 5.1. Enzyme and neuroadaptation dynamics in the 2 day drug treatment followed by abrupt withdrawal Figure Behavior of chloride current in the 2 day drug treatment Figure Dose profile (a) and drug amount in the brain (b) in the 6 day drug treatment followed by abrupt withdrawal... 5 Figure Enzyme and neuroadaptation dynamics in the 6 day drug treatment followed by abrupt withdrawal Figure Behavior of chloride current in the 6 day drug treatment Figure Progression of enzyme induction in 2 days of continuous PB use Figure Comparison of tolerance dynamics generated by the model (a) against real data (b) from Gay et al (1983) Figure Tolerance and dependence indicators for 6 days of continuous PB intake, (a) Model output, (b) Real data Figure Differences in withdrawal dynamics between a partially dependent (2 day user) and a completely dependent (6 day user) Figure 6.1. Dose profiles (a) and drug profiles in brain tissue (b) of both a healthy and an epileptic individual in 2 days of continuous PB use Figure 6.2. Enzyme and neuroadaptation dynamics in both a healthy and an epileptic individual taking PB for the last 6 days Figure 6.3. Chloride current in a healthy and an epileptic individual) Figure 6.4. Flurbiprofen average clearance as influenced by fluconazole pre-treatment Figure 6.5. Dose profiles (a) and drug amounts in the brain (b) with and without fluconazole pre-treatment Figure 6.6. Enzyme and neuroadaptation dynamics with and without fluconazole pre-
10 x treatment Figure 6.7. Enzyme and neuroadaptation dynamics in different dosing schemes (No feedback to increase the doses) Figure 6.8. Comparative behavior of chloride current (No feedback to increase the doses) Figure 6.9. Difference in the extent of tolerance development w.r.t dosing schemes (Feedback allowed to increase doses) Figure 6.1. Neuroadaptation dynamics for different dosing schemes (Feedback allowed to increase doses) Figure Dependence dynamics for different dosing schemes (Feedback allowed to increase doses) Figure Behavior of chloride current in different dosing schemes (Feedback allowed to increase doses) Figure 7.1. Dynamics of an unsuccessful withdrawal regimen after partial dependence Figure 7.2. Severity of withdrawal signs after an unsuccessful dosing strategy in partial dependence Figure 7.3. Dynamics in a successful withdrawal regimen after partial dependence Figure 7.4. Severity of withdrawal signs after a successful dosing strategy in partial dependence Figure 7.5. Results for an unsuccessful withdrawal regimen after complete dependence Figure 7.6. Severity of withdrawal signs after an unsuccessful dosing strategy in complete dependence Figure 7.7. Results for a gradual withdrawal regimen of 3 days following a 6 day drug treatment Figure 7.8. Severity of withdrawal signs after a successful dosing strategy in complete dependence... 77
11 xi LIST OF TABLES Table 1.1. Classification and properties of barbiturates... 3 Table 4.1. Main pharmacokinetic parameters used in the model Table 4.2. Other pharmacokinetic parameters Table 5.1. Initial values for the stocks... 37
12 xii LIST OF ABBREVIATIONS Adptn Arterial Braincapil Braintis C ClCur ClCurWOP B CNS CYP Eff GABA GI Ind Induc M Norm P PB Q Readptn Real ThresholdSedat V Venous Adaptation Arterial Blood Brain Capillary Brain Tissue Concentration (of phenobarbital in) Chloride Current Chloride Current Without Phenobarbital Central Nervous System Cytochrome P Effect Gamma Amino Butyric Acid Gastrointestinal Indicated Induction Amount (of phenobarbital in) Normal Tissue-Blood Partitition Coefficient (of phenobarbital in) Phenobarbital Blood Volumetric Flow Rate (through) Re-adaptation Realized Sedation Threshold Volume (of) Venous Blood
13 1 1. INTRODUCTION Barbiturates are classified as central nervous system (CNS) depressants. They act generally on the CNS. In low doses, they cause sedation and as the dose is increased, the user experiences hypnosis (i.e. sleep). Further increase in the dose results in anesthesia and finally coma. Overdose of barbiturates causes severe respiratory depression and may lead to death. For instance, Jimi Hendrix, the famous rock artist, died of barbiturate overdose in the year 197. Because of having high abuse potential, they are being replaced by the safer benzodiazepines. Figure 1.1 gives an idea about the relative safety of barbiturates and benzodiazepines. Figure 1.1. Relative safety of barbiturates and benzodiazepines (Katzung 24) The dose-effect relationship of barbiturates is rather linear and lethal overdoses are more likely. On the other hand, this relationship is saturable for benzodiazepines. At high doses, as the dose is further increased, CNS depression stays almost constant. This enables a wider margin of safety.
14 2 Despite their high abuse potential, barbiturates are still being used as anticonvulsants (i.e. anti-epileptic drugs), intravenous anesthetics, and death inducing agents (Hardman and Limbird, 21). Furthermore, a lot of people still use barbiturates for sedation or to fall asleep. Alarmingly, a statistical study revealed that the frequency of barbiturate use among twelfth grade high school students in the U.S. has increased slightly over the last few years (See Figure 1.2 below). Figure 1.2. Frequency of barbiturate use among twelfth grade high school students (From Barbiturates are classified with respect to their onset and duration of action. However, the action mechanism is the same for all barbiturates. Different barbiturate classes are tabulated in Table 1.1.
15 3 Table 1.1. Classification and properties of barbiturates (Hardman and Limbird, 21) CLASS Ultra-shortacting Short-acting Intermediateacting Long-acting COMPOUND (TRADE NAMES) Methohexital (BREVITAL) Thiopental (PENTHOTAL) Pentobarbital (NEMBUTAL) Secobarbital (SECONAL) Amobarbital (AMYTAL) Aprobarbital (ALURATE) Butabarbital (BUTISOL, others) ROUTES OF ADMINISTRATION HALF- LIFE, HOURS THERAPEUTIC USES I.V. 3-5 * Induction and/or maintenance of anesthesia I.V., rectal 8-1 * Induction and/or maintenance of anesthesia, preoperative sedation, emergency management of seizures Oral, I.M., I.V., rectal 15-5 Insomnia, preoperative sedation, emergency management of seizures Oral, I.M., I.V., rectal 15-4 Insomnia, preoperative sedation, emergency management of seizures Oral, I.M., I.V. 1-4 Insomnia, preoperative sedation, emergency management of seizures Oral Insomnia Oral 35-5 Insomnia, preoperative sedation Butalbital Oral Marketed in combination with analgesic agents Mephobarbital (MEBARAL) Phenobarbital (LUMINAL, others) Oral 1-7 Seizure disorders, daytime sedation Oral, I.M., I.V Seizure disorders, status epilepticus, daytime sedation I.M.: intramuscular injection, I.V.: intravenous administration * Value represents terminal half-life due to metabolism by liver; redistribution following intravenous administration produces effects lasting only a few minutes
16 4 Other than the therapeutic uses mentioned in Table 1.1, some barbiturates have had different uses. For example, other than its common use as an inducer of anesthesia, the ultra-short acting thiopental is used in large doses in the United States to execute prisoners on death row. In lower doses, it is sometimes used as a truth serum. The drug does not itself force people to tell the truth, but is thought to make subjects more likely to be caught off guard when questioned (Stevens and Bannon, 27). Barbiturate use can cause dependence. This dependence may be psychological in the initial stages of barbiturate treatment. However, as treatment continues, tolerance and then physical dependence develops. As people develop tolerance for barbiturates, they may need more of the drug to get the desired effect. This can lead to an overdose. As Weil and Rosen (24) point out in From Chocolate to Morphine, People who get in the habit of taking sleeping pills every night to fall asleep might start out with one a night, progress to two, and then graduate to four to get the same effect. One night the dose they need to fall asleep might also be the dose that stops their breathing." Overdoses occur because tolerance to the lethal effects of the drug is less than tolerance to its therapeutic effects (e.g. sedation). In physical dependence, the user experiences difficulties in stopping drug treatment. Upon discontinuation of the drug, the user experiences a withdrawal syndrome in which he/she goes through a state of rebound hyperexcitability manifested as excessive nightmarish dreaming, restlessness, irritability, and convulsions (Liska, 21). Although their use is decreasing, mechanism of action of barbiturates is just recently being clarified. Before reviewing the mechanism, it would be useful to briefly overview first the subject of neurotransmission and then pharmacokinetics Neurotransmission in the Central Nervous System Neurotransmission means the communication of nerve cells (i.e. neurons). This is accomplished by billions of interconnected neurons. The point where two neurons meet is called a synapse. Different types of synapses exist and these are shown in Figure 1.3.
17 5 Figure 1.3. Different types of synapses (top). A schematic representation of neurotransmission (bottom) (From The message between two neurons is conveyed through synapses via substances called neurotransmitters. Neurotransmitters are stored in specialized sacs (i.e. vesicles) inside the presynaptic nerve endings (i.e. nerve terminals). When a reversal of electrical charge is experienced in the nerve terminal, the vesicles translocate and bind to the neuronal membrane. This process is called docking. The reversal of charge is called the action potential. It is accomplished through an influx of sodium ions and efflux of potassium ions through specialized ion channels located on the axon of the presynaptic neuron. This depolarization is conveyed to the nerve ending and causes ion channels to open and allow an influx of calcium. The influx of calcium ions induces the release of the neurotransmitter to the synaptic cleft by exocytosis of the docked vesicles. The neurotransmitter then travels to the postsynaptic neuron and binds to specific receptor proteins on its membrane and changes the membrane electrical potential. If the neurotransmitter is excitatory, an influx of sodium ions to the postsynaptic neuron causes depolarization and this initiates an action potential in the neuron. However, if the
18 6 neurotransmitter is inhibitory, an influx of chloride and potassium ions occurs which hyperpolarizes the membrane and thus an action potential is inhibited (Hardman and Limbird, 21). In figure 1.4, inhibitory and excitatory neurotransmission are summarized. Figure 1.4. Steps in excitatory and inhibitory neurotransmission (Hardman and Limbird, 21) The most widespread excitatory and inhibitory transmitters in the CNS are glutamate and gamma-aminobutyric acid (GABA), respectively (Powis and Bunn, 1995). As mentioned previously, there exist receptors on neuronal membranes that are specialized to bind neurotransmitters. Each receptor is specialized to bind a specific type of neurotransmitter. Furthermore, there are many sub-types of a receptor for a specific
19 7 neurotransmitter and functions of each of these subunits are modulated by different mechanisms (Hardman and Limbird, 21) Definition of Pharmacokinetics There are several phases before an administered drug causes a response. After administration, the drug goes through many phases during which it may lose effectiveness. After oral administration, the drug must dissolve in stomach fluids, and it must be absorbed from the gastrointestinal tract. Once absorbed, it is directly transported to the liver via the hepatic portal vein. The metabolism in liver at this stage is referred to as first-pass metabolism. In drug development, it is aimed to design drugs that have little first-pass metabolism since it has a negative impact on drug efficacy. Furthermore, a drug may also undergo elimination in different regions such as the gastrointestinal wall which too is an undesired property. After first-pass metabolism, the remaining drug enters blood circulation and reaches the target organ. There, it binds its receptor to exert its effect. While in blood circulation, the drug is transported to the liver once more and it undergoes further elimination. Also while in circulation, it may bind to blood plasma proteins or tissues of different organs. Once bound, a drug molecule is ineffective. This process of drug delivery in the body is referred to as pharmacokinetics Pharmacokinetics of Barbiturates Most barbiturates are rapidly absorbed into the blood following oral intake. The most important factor that plays a role in the entrance of a barbiturate into the brain is its lipid solubility. To exemplify the differences in pharmacokinetic profiles of barbiturates, we consider two barbiturates: ultra-short acting thiopental and long acting phenobarbital (See Table 1.1). Due to its high lipid solubility, the ultra-short acting thiopental has a very rapid onset of effects in the CNS. In comparison, the long acting phenobarbital has low lipid solubility and thus penetrates into the brain slower.
20 8 In order to be cleared from the body, barbiturates must be transformed into more water-soluble forms so that they can be filtered in the kidneys. Only insignificant quantities (less than 1per cent) of thiopental are excreted unchanged in the urine. Unlike thiopental, 2 to 3 percent of the administered dose of phenobarbital is excreted unchanged. The elimination-half life of phenobarbital is 4 to 5 days. For thiopental, the situation is much more complex. Upon intravenous administration, thiopental rapidly penetrates into the brain due to its very high lipid solubility and if the dose is sufficient, produces loss of consciousness in one circulation time. The blood plasma-brain equilibrium is reached in less than a minute. After that, thiopental diffuses out of the brain and out of other tissues that receive high blood supply and is redistributed to all the remaining less perfused tissues such as muscle and fat. It is because of this rapid redistribution that a single dose of thiopental is very short acting (Katzung, 24). The redistribution phenomenon causes the half-life of thiopental to be time dependent. Initially, the fall in plasma concentration is very rapid corresponding to a half-life of less than ten minutes. It is denoted as t 1/2α in Figure 1.5 below. After redistribution to less perfused areas, the fall of concentration slows down. The half-life increases to more than ten hours. This half-life is denoted as t 1/2β in the figure. Figure 1.5. Blood plasma concentration time data for a single IV dose of thiopental (From
21 Action mechanism of barbiturates It was shown that barbiturates exert their CNS-depressant effects by both potentiating the inhibitory effects of GABA and suppressing excitatory effects of glutamate. However, suppression of excitatory neurotransmission does not contribute to their sedative/hypnotic effects (Powis and Bunn, 1995; Joo et al., 1999). At low to moderate concentrations, barbiturates bind to the GABA A receptor. The GABA A receptor is a sub-type of GABA receptors which is classified as a ligand-gated ion channel meaning that the binding of a ligand (a molecule) to the receptor causes the ion channel to open. The GABA A receptor is composed of different sub-units. The distribution of these sub-units in the CNS is widespread and heterogeneous and this heterogeneity has yet to be fully defined (Hardman and Limbird, 21). Schematically, the GABA A receptorion channel complex is as in Figure 1.6. Figure 1.6. GABA A receptor-chloride channel complex. There are five binding sites (subunits) on the complex (From By binding to its specific site, barbiturates enhance the inhibitory chloride ion currents mediated by GABA. Essentially, barbiturates increase the time for which GABAactivated channels are open. At higher concentrations, they activate the chloride channels even in the absence of GABA. This action is regarded as postsynaptic inhibition. In
22 1 addition to postsynaptic effects, barbiturates induce GABA-mediated presynaptic inhibition as well. This takes place in axo-axonic synapses (See Figure 1.3). GABA released from the ending of the inhibitory neuron binds to GABA receptors on the terminal of the excitatory neuron and causes a modest depolarization which decreases excitatory neurotransmitter release. It was also shown that especially at higher concentrations, barbiturates directly suppress excitatory transmission mediated by glutamate. The postand pre-synaptic inhibition effects of barbiturates are shown in Figure 1.7. Figure 1.7. Pre- and post-synaptic neuroinhibition by barbiturates (Powis and Bunn, 1995) Also, at anesthetic concentrations, barbiturates inhibit calcium influx to the presynaptic nerve ending and thus reduce transmitter release. In addition to these, barbiturates reduce axonal conduction through ion channels and thus increase the threshold for electrical excitability and decrease the rate of rise of the action potential. However, these
23 11 effects are realized at very high concentrations which are practically irrelevant (Powis and Bunn, 1995) Development of Tolerance and Dependence to Barbiturates Barbiturates have been shown to cause the phenomenon of enzyme induction. In the liver, there exists a system of enzymes that are responsible for converting many endogenous and exogenous substances into active and/or inactive forms. The so-called cytochrome P45 family of enzymes constitutes the majority of the enzyme population in the liver (Hardman and Limbird, 21). By convention, cytochrome enzymes have the prefix CYP. The CYP enzymes catalyze various destructive reactions such as oxidation. The inducing effect of barbiturates causes more enzymes to be synthesized and thus a faster metabolism of the substrates of these enzymes. When the set of substrates include the drug itself, this is called autoinduction. In time, a tolerance to the barbiturate occurs and higher doses are required to induce the same drug effect. Among barbiturates, phenobarbital (will be denoted by PB hereafter) is the most potent inducer of CYP2C subfamily of enzymes. Since PB itself is mostly metabolized by this subfamily of enzymes (Tanaka, 1999), it has autoinduction properties. This was also reported by Magnusson (27). Induction of enzymes by PB in rats is studied by Magnusson et al. (26). Their purpose is to characterize the magnitude, time course, and specificity of PB mediated enzyme induction, and to develop an integrated pharmacokinetic model that represents the change in the activities of different CYP enzymes. In another study, Raucy et al. (22) work with human liver cells in vitro to investigate the extent of induction of CYP2C enzymes by several inducers including PB. The mechanism of induction is not fully understood. Nevertheless, there is progress. A variety of drugs and xenobiotics cause enzyme induction and each is believed to have its own mechanism. It is believed that inside liver cells, there exist several receptors that respond to different types of chemicals. These receptors are called nuclear receptors. An excellent review on the topic is provided by Handschin and Meyer (23). It is believed
Nursing 113 Pharmacology Principles 1. The study of how drugs enter the body, reach the site of action, and are removed from the body is called a. pharmacotherapeutics b. pharmacology c. pharmacodynamics
DRUGS AND THE BRAIN Most of the psychological and behavioural effects of psychoactive drugs is due the interaction they have with the nerve cells in the CNS (which includes the brain and peripheral nervous
Absorption of Drugs Absorption is the transfer of a drug from its site of administration to the bloodstream. The rate and efficiency of absorption depend on the route of administration. For IV delivery,
Benzodiazepines: A Model for Central Nervous System (CNS) Depressants Objectives Summarize the basic mechanism by which benzodiazepines work in the brain. Describe two strategies for reducing and/or eliminating
Name: Questions on The Nervous System and Gas Exchange Directions: The following questions are taken from previous IB Final Papers on Topics 6.4 (Gas Exchange) and 6.5 (Nerves, hormones and homeostasis).
5.1. SYNAPTIC TRANSMISSION CHAPTER 5 SIGNALLING IN NEURONS One of the main functions of neurons is to communicate with other neurons. An individual neuron may receive information from many different sources.
Principles of Pharmacokinetics and Pharmacodynamics Kevin K. Caldwell, Ph.D. PHARMACOKINETICS The actions of the body on the drug VS PHARMACODYNAMICS The actions of the drug on the body Katzung, 8th ed.,
Nervous Systems: Neuron Structure and Function Integration An animal needs to function like a coherent organism, not like a loose collection of cells. Integration = refers to processes such as summation
Holy Family Hospital Dr Sarah Daniels April 2009 1 Topics to be covered Pharmacokinetics Pharmacodynamics Drug use in special groups Infants Children Elderly Pregnancy Polypharmacy 2 Pharmacokinetics Pharmacokinetics:
Alcohol Use Dates Back 7,000 to 10,000 Years Though Scientists Still Debate the Mechanisms of Hangovers Proposed Causes of Hangovers Acute ethanol withdrawal Ethanol can alleviate symptoms Acetaldehyde
Neural Communication by Richard H. Hall, 1998 Forces and Membranes Now that we've considered the structure of the cells of the nervous system it is important to address their principal function, communication.
Many Types of Xanthenes Stimulants Xanthenes and Caffeine Psychology 472 Pharmacology of Psychoactive Drugs Listen to the audio lecture while viewing these slides Xanthenes Theophylline (Tea) Theobromine
Slide 1: Introduction Introduce the purpose of your presentation. Indicate that you will explain how the brain basically works and how and where drugs such as heroin and cocaine work in the brain. Tell
Resting membrane potential ~ -70mV - Membrane is polarized (ie) Electrical charge on the outside of the membrane is positive while the electrical charge on the inside of the membrane is negative Changes
Absorption and Half-Life Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand Objectives Understand the physiological determinants of rate and extent of absorption
Bi 360: Midterm Review Basic Neurobiology 1) Many axons are surrounded by a fatty insulating sheath called myelin, which is interrupted at regular intervals at the Nodes of Ranvier, where the action potential
2 Neurophysiology 2.1 Equilibrium Potential An understanding of the concepts of electrical and chemical forces that act on ions, electrochemical equilibrium, and equilibrium potential is a powerful tool
PART I: Neurons and the Nerve Impulse Identify each of the labeled structures of the neuron below. A. B. C. D. E. F. G. Identify each of the labeled structures of the neuron below. A. dendrites B. nucleus
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Pain is one of the most common reasons for a patient to seek medical attention. Moderate or severe intensity pain can be acute
2013 ANATOMY & PHYSIOLOGY Sample Tournament Station A: Use the diagram in answering Questions 1-5. 1. Give the name and functions of the structure labeled A on the diagram. 2. Give the name and functions
t/.drugexcretion AINTRAVENOUSDOSE 36848765430TIME(hours) t/ Drug Excretion Dr. Robert G. Lamb Professor Pharmacology & Toxicology Drug Excretion and Clearance Drug Excretion: is the movement of drug from
Objectives Basic Pharmacology & Pharmokinetics Discuss drug nomenclature and classifications Describe the processes involved with pharmacokinetics and pharmacodynamics Discuss potential drug interactions
BSc in Medical Sciences with PHARMACOLOGY Course Director Dr Christopher John Module Leaders Dr Robert Dickinson (Module 1) Dr Anabel Varela Carver (Module 2) Dr Sohag Saleh (Module 3) Course Administrator
The Nervous System Nervous system links sensory receptors and motor effectors Sensory (afferent) neurons carry impulses from receptors Motor (efferent) neurons carry impulses to effectors - muscles and
Module 3 Brain s Building Blocks Structure of the Brain Genes chains of chemicals that are arranged like rungs on a twisting ladder there are about 100,000 genes that contain chemical instructions that
PHC 313 The 7 th. Lecture Adrenergic Agents Introduction Introduction Adrenergic agents are a broad class of agents employed in the treatment of many disorders. They are those chemical agents that exert
Drugs, The Brain, and Behavior John Nyby Department of Biological Sciences Lehigh University What is a drug? Difficult to define Know it when you see it Neuroactive vs Non-Neuroactive drugs Two major categories
Downers/Depressants (pages 40-50) Read pages 49-54, 59-60, and 78-79 of the booklet, Street Drugs. Pages 40-50 of the text. Narcotics: Prescription Origin: Southeast Asia, Southwest Asia, and in the Western
Anesthesia and Renal Failure In renal failure, the induction dose of which of the following should be decreased? Propofol Ketamine Thiopental Etomidate Induction Anesthetics Propofol: undergoes hepatic
Heroin Heroin is an opiate drug that is synthesized from morphine, a naturally occurring substance extracted from the seed pod of the Asian opium poppy plant. Heroin usually appears as a white or brown
Hormones & Chemical Signaling Part 2 modulation of signal pathways and hormone classification & function How are these pathways controlled? Receptors are proteins! Subject to Specificity of binding Competition
1) The resting membrane potential: a. Is much closer to the equilibrium for Na+ than to the equilibrium potential for K+. b. Is much closer to the equilibrium for K+ than to the equilibrium potential for
AP Biology I. Nervous System Notes 1. General information: passage of information occurs in two ways: Nerves - process and send information fast (eg. stepping on a tack) Hormones - process and send information
-1- Introduction to Body Fluids Graphics are used with permission of : adam.com (http://www.adam.com/) Benjamin/Cummings Publishing Co (http://www.awl.com/bc) Page 1: Introduction to Body Fluids The fluids
Introduction to Body Fluids Graphics are used with permission of: Pearson Education Inc., publishing as Benjamin Cummings (http://www.aw-bc.com) Page 1: Introduction to Body Fluids The fluids in your body
Drugs Change the Way Neurons Communicate L E S S O N 3 Explain/Elaborate Source: Principles of Neural Science, 3rd edition, Eric R. Kandel, James H. Schwartz, and Thomas M. Jessell. The McGraw-Hill Companies.
Heroin Heroin is an opiate drug that is synthesized from morphine, a naturally occurring substance extracted from the seed pod of the Asian opium poppy plant. Heroin usually appears as a white or brown
Name: Teacher: Olsen Hour: The Nervous System: Part 1 Textbook p216-225 41 In all exercises, quizzes and tests in this class, always answer in your own words. That is the only way that you can show that
NEURON AND NEURAL TRAMSMISSION: ANATOMY OF A NEURON NEURON AND NEURAL TRAMSMISSION: MICROSCOPIC VIEW OF NEURONS A photograph taken through a light microscope (500x) of neurons in the spinal cord. NEURON
Local Anesthetics History The first local anesthetics were cocaine and procaine (Novacain) developed in lt late 1800 s They were called esters because of their chemical composition Esters had a slow onset
Proteins Molecular Physiology: Enzymes and Cell Signaling Polymers of amino acids Have complex 3D structures Are the basis of most of the structure and physiological function of cells Binding Much of protein
2006 7.012 Problem Set 6 KEY ** Due before 5 PM on WEDNESDAY, November 22, 2006. ** Turn answers in to the box outside of 68-120. PLEASE WRITE YOUR ANSWERS ON THIS PRINTOUT. 1. You create an artificial
Harvard-MIT Division of Health Sciences and Technology HST.151: Principles of Pharmocology Instructor: Dr. David Standaert Standaert 1 Neuropharmacology II Antidepressants and Sedatives Depression A frequent
Mechanisms of action of AEDs Wolfgang Löscher Department of Pharmacology, Toxicology and Pharmacy University of Veterinary Medicine Hannover, Germany and Center for Systems Neuroscience Hannover, Germany
Heroin Heroin is a synthetic opiate drug that is highly addictive. It is made from morphine, a naturally occurring substance extracted from the seed pod of the Asian opium poppy plant. Heroin usually appears
CHAPTER 6 PRINCIPLES OF NEURAL CIRCUITS. 6.1. CONNECTIONS AMONG NEURONS Neurons are interconnected with one another to form circuits, much as electronic components are wired together to form a functional
Pharmacotherapy in the Elderly Judy MY Wong email@example.com Percentage of population with prescription and number of medication per individual increase with age Definitions Pharmacology: pharmakon
Treatments for Major Depression Drug Treatments The two (2) classes of drugs that are typical antidepressants are: 1. 2. These 2 classes of drugs increase the amount of monoamine neurotransmitters through
C H A P T E R 1 11 HUMAN ANATOMY & PHYSIOLOGY THE HUMAN BODY: AN ORIENTATION FUNDAMENTALS OF THE NERVOUS SYSTEM & NERVOUS TISSUE C H A P T E R 1 PART I HUMAN ANATOMY & PHYSIOLOGY FUNDAMENTALS OF THE NERVOUS
Prior Authorization Guideline Guideline: CSD - Suboxone Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Analgesics and Antipyretics (Opiate Partial Agonists) Client: County of San
SEROTONIN AND PAIN LEARNING OBJECTIVES At the end of lecture students should be able to know, Chemistry of serotonin. Understand the role of serotonin in CNS. Understand the relationship of serotonin and
Chapter 1 Dissolved Oxygen in the Blood Say we have a volume of blood, which we ll represent as a beaker of fluid. Now let s include oxygen in the gas above the blood (represented by the green circles).
The effects that are in play when the enzyme-substrate complex forms: The proximity effect: The orientation effect: The catalytic effect: The energy effect: The enzyme has to join up with the substrate
Actions of Hormones on Target Cells Graphics are used with permission of: Pearson Education Inc., publishing as Benjamin Cummings (http://www.aw-bc.com) Page 1. Actions of Hormones on Target Cells Hormones
Diabetes mellitus Lecture Outline I. Diagnosis II. Epidemiology III. Causes of diabetes IV. Health Problems and Diabetes V. Treating Diabetes VI. Physical activity and diabetes 1 Diabetes Disorder characterized
Keystone Review Practice Test Module A Cells and Cell Processes 1. Which characteristic is shared by all prokaryotes and eukaryotes? a. Ability to store hereditary information b. Use of organelles to control
Drug Metabolism and Pharmacokinetics in Drug Discovery: A Primer For Bioanalytical Chemists, Part II Chandrani Gunaratna, Ph.D. Bioanalytical Systems, Inc. 2701 Kent Avenue West Lafayette, IN 47906-1382
REVIEW SHEET EXERCISE 3 Neurophysiology of Nerve Impulses Name Lab Time/Date ACTIVITY 1 The Resting Membrane Potential 1. Explain why increasing extracellular K + reduces the net diffusion of K + out of
Regulation of carbohydrate metabolism Intracellular metabolic regulators Each of the control point steps in the carbohydrate metabolic pathways in effect regulates itself by responding to molecules that
7 Answers to end-of-chapter questions Multiple choice questions 1 B 2 B 3 A 4 B 5 A 6 D 7 C 8 C 9 B 10 B Structured questions 11 a i Maintenance of a constant internal environment within set limits i Concentration
The Neuropharmacology of Drugs of Abuse 3 rugs of abuse interact with the neurochemical mechanisms of the brain. Some of these interactions are directly related to the reinforcing properties of a drug,
Philip Moore DO, Toxicology Fellow, PinnacleHealth Toxicology Center Joanne Konick-McMahan RN MSRN, Staff RN, PinnacleHealth I. II. Background A. AWS can occur in anyone who consumes alcohol B. Risk correlates
Review of Pharmacological Pain Management CHAMP Activities are possible with generous support from The Atlantic Philanthropies and The John A. Hartford Foundation The WHO Pain Ladder The World Health Organization
Carbon Balance, Respiration and Environment K. Raja Reddy Krreddy@pss.msstate.edu Carbon Balance, Respiration and Environment Goals and learning objectives are to: Understand the respiration costs associated
Alcohol Withdrawal Syndrome & CIWA Assessment Alcohol Withdrawal Syndrome is a set of symptoms that can occur when an individual reduces or stops alcoholic consumption after long periods of use. Prolonged
~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 3 of 4 Michael J. Sanfelippo, M.S. Technical Director, Coagulation Services Session 3 Topics Direct Thrombin Inhibitors:
3: Neurophysiology of Nerve Impulses (Part 2) Activity 5: The Action Potential: Measuring Its Absolute and Relative Refractory Periods Interval between stimuli Stimulus voltage (mv) Second action potential?
Chapter 3 Pharmacokinetics & Pharmacodynamics Pharmacokinetics & Pharmacodynamics Pharmacodynamics governs the concentration-effect part of the interaction, whereas pharmacokinetics deals with the dose-concentration
Overactive bladder is a common condition thought to FADE UP TO WIDE SHOT OF FEMALE MODEL WITH TRANSPARENT SKIN. URINARY BLADDER VISIBLE IN PELVIC REGION affect over 16 percent of adults. It affects men
1 Alzheimer Disease (AD) 2 Alzheimer's disease is a progressive degenerative disease that attacks the brain and results in impaired memory, thinking and behavior. It was first described by Dr. Alois Alzheimer
POST-TEST University of Wisconsin Hospital & Clinics True/False/Don't Know - Circle the correct answer T F D 1. Changes in vital signs are reliable indicators of pain severity. T F D 2. Because of an underdeveloped
Glutathione and Oxidative Stress - Part I By: James L. Holly, MD Oxidative Stress refers to effects from endogenous (produced in the body) toxins (free radicals) produced in the body by normal metabolism
Drug Abuse (chapter 18) 1. Definitions iti a. positive vs. negative reinforcement b. tolerance vs. sensitization c. drug classes 2. Neural Mechanisms of Re einforcement a. mesolimbic dopamine system b.
The Neuron and the Synapse The Neuron Functions of the neuron: Transmit information from one point in the body to another. Process the information in various ways (that is, compute). The neuron has a specialized
Chapter 25: Metabolism and Nutrition Chapter Objectives INTRODUCTION 1. Generalize the way in which nutrients are processed through the three major metabolic fates in order to perform various energetic
Physiologic Anatomy of Neuron Basic parts of neuron (nerve cell) Cell body Dendrites Axon Axon hillock Axon terminals Action potentials are initiated at the axon hillock, and conducted throughout a nerve
Parts of the Nerve Cell and Their Functions Silvia Helena Cardoso, PhD [ 1. Cell body] [2. Neuronal membrane] [3. Dendrites] [4. Axon] [5. Nerve ending] 1. Cell body The cell body (soma) is the factory
Grade: 10,11, and 12 Subject: Anatomy and Physiology First Marking Period Define anatomy and physiology, and describe various subspecialties of each discipline. Describe the five basic functions of living
1 PHOSPHATE-SANDOZ Tablets (High dose phosphate supplement) PHOSPHATE-SANDOZ PHOSPHATE-SANDOZ Tablets are a high dose phosphate supplement containing sodium phosphate monobasic. The CAS registry number
What Alcohol Does to the Body Chapter 25 Lesson 2 Short-Term Effects of Drinking The short-term term effects of alcohol on the body depend on several factors including: amount of alcohol consumed, gender,
Case Study: Factors that Affect Blood Pressure Instructor Version Goal This activity (case study and its associated questions) is designed to be a student-centered learning activity relating to the factors
Nurses Self Paced Learning Module on Pain Management Dominican Santa Cruz Hospital Santa Cruz, California Developed by: Strategic Planning Committee Dominican Santa Cruz Hospital 1555 Soquel Drive Santa
Page 1 DRUGS FOR GLUCOSE MANAGEMENT AND DIABETES Drugs to know are: Actrapid HM Humulin R, L, U Penmix SUNALI MEHTA The three principal hormones produced by the pancreas are: Insulin: nutrient metabolism:
CDER Final 10/25/11 Blueprint for Prescriber Continuing Education Program I. Introduction: Why Prescriber Education is Important Health care professionals who prescribe extended-release (ER) and long-acting
7.013 Problem Set 6-2013 Question 1 a) Our immune system is comprised of different cell types. Complete the table below by selecting all correct cell types from the choices provided. Cells types that Participate